Drugs / ENSEREPTIDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00860080 | Mar → Apr 2009 | adhesions of uterus | PharmaSurgics AB | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01022242 | Dec 2009 → May 2012 | — | Pergamum AB | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-09-16 | Pharmaceutical Research Network | Regulatory 파마리서치프로덕트, 스웨덴 식약처 임상 적합 승인 pharmaresearch.com ↗
파마리서치프로덕트(대표 정상수•안원준)는 스웨덴 '리포펩타이드AB'(Lipopeptide AB)와 공동개발 중인 의약품(PXL01)이 스웨덴 식약처로부터 2상 임상 적합 승인을 받았다고 밝혔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-09-16 | Pharmaceutical Research Network | 파마리서치프로덕트, 스웨덴 식약처 임상 적합 승인 pharmaresearch.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENSEREPTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095372 ↗ |
| Known as | PXL01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01022242 ↗ |
| Modality | Peptide | “PXL01 is a synthetic peptide sequentially derived from human lactoferrin.” NCT00860080 ↗ |
| Route | Subcutaneous | “10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.” NCT00860080 ↗ |